Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 6/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.32 |
| ▸ | MC4R | P32245 | 1/20 | 0.32 |
| ▸ | MC3R | P41968 | 1/20 | 0.32 |
| ▸ | MC1R | Q01726 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | PLAU | P00749 | 2/20 | 0.31 |
| ▸ | PLAUR | Q03405 | 2/20 | 0.31 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4558735 | 0.80 | SLC6A4 (0.49) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL7133381 | 0.75 | TAAR1 (0.36) | SLC6A4SLC6A2SLC6A3GSK3B | |
| SCHEMBL11251072 | 0.73 | SLC6A4 (0.55) | SLC6A4SLC6A2SLC6A3OPRD1LMNA | |
| SCHEMBL4557726 | 0.70 | PPID (0.40) | LMNAGSK3B | |
| SCHEMBL11697763 | 0.68 | CAPN1 (0.38) | LMNAGSK3B | |
| SCHEMBL11696742 | 0.68 | TAAR1 (0.55) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL11695006 | 0.67 | GABRA1 (0.40) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL4558733 | 0.67 | HPGD (0.34) | GSK3B | |
| SCHEMBL3047306 | 0.65 | TAAR1 (0.34) | GSK3B | |
| SCHEMBL11693436 | 0.65 | GSK3B (0.38) | LMNAGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7501407-B2 | Pyrimidine A2B selective antagonist compounds, their synthesis and use | OSI PHARMACEUTICALS, INC. (US) | 2009-03-10 | — | — | US | disclosed |
| US-20050119271-A1 | Pyrimidine A2B selective antagonist compounds, their synthesis and use | OSI PHARMACEUTICALS, INC. | 2005-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119271-A1 | Pyrimidine A2B selective antagonist compounds, their synthesis and use | ADORA2B, ADORA2A, ADORA3 | SLC6A4 260/4885DPP4 2678/4885SLC6A2 153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.